Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Liraglutide (Victoza) and tirzepatide (Mounjaro) are both injectable medications used to treat Type 2 diabetes. They help control blood sugar levels but are not insulin. However, they have some differences. Liraglutide is a GLP-1 receptor agonist, while tirzepatide is a dual GIP and GLP-1 receptor agonist. Liraglutide is injected once daily, whereas tirzepatide is injected once weekly, which might be more convenient for some people. Both medications can cause side effects like nausea, vomiting, and diarrhea, but tirzepatide may also affect your heart rate and cause eye problems related to high blood sugar. Liraglutide is available as a generic, while tirzepatide is only available as a brand-name medication. Both medications carry a risk of thyroid cancer and pancreatitis, so it's important to discuss your medical history with your healthcare provider before starting either one.
Victoza (liraglutide)
Mounjaro (tirzepatide)
Victoza (liraglutide)
Mounjaro (tirzepatide)
Summary of Victoza vs. Mounjaro
Summary for GLP-1 agonist
Prescription only
Victoza (liraglutide) is a medication that's injected once a day. It helps lower blood sugar levels in people 10 years and older with Type 2 diabetes when used with a nutritious diet and regular exercise. It can also help lower the risk of heart-related problems in adults with Type 2 diabetes and heart disease. Victoza (liraglutide) belongs to the drug class called GLP-1 agonists. The medication comes as single-dose prefilled pens and is injected under the skin. It can cause side effects like nausea, vomiting, diarrhea, and constipation. Victoza (liraglutide) is available as both a brand-name and generic medication.